Physician profile
Benjamin Morehead
NPI 1124447719
$2,301.63
in general payments reported to CMS, 2019-2025
21 companies · $371 in 2025
The $371 reported for 2025 was more than what 87% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $196 · 2021: $460 · 2022: $126 · 2023: $150 · 2024: $57.41 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $324.04 | 2019-2025 | |
| Abbvie INC. | $209.42 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $183.03 | 2021-2023 | Xarelto |
| Mallinckrodt Enterprises LLC | $181.17 | 2019 | |
| United Therapeutics Corporation | $174.64 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $173.48 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.13 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $148.80 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $128.05 | 2019-2021 | |
| Genentech USA, INC. | $115.53 | 2019 | |
| Astellas Pharma US INC | $114.16 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $106.01 | 2019-2021 | |
| Abiomed | $94.24 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $41.15 | 2022 | |
| Mallinckrodt Hospital Products INC. | $35.35 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $26.59 | 2019-2020 | |
| Glaxosmithkline, LLC. | $26.42 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.45 | 2021 | |
| Chiesi USA, INC. | $17.30 | 2025 | Kengreal, Cleviprex |
| Vapotherm INC | $12.13 | 2020 | |
| Tetraphase Pharmaceuticals, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Morehead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.